(SUN-131(Senju Pharmaceutical Co., Ltd.)) - 药物靶点：GR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

SUN 131、SUN-131、SUN-131 TDS

靶点

GR

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤眼部疾病

在研适应症-

非在研适应症

霰粒肿

原研机构

Senju Pharmaceutical Co., Ltd.

在研机构-

非在研机构

Senju-USA, Inc.

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 SUN-131(Senju Pharmaceutical Co., Ltd.) 相关的临床试验

NCT03248440 / Completed临床3期

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion (SUN-131-03)

This protocol for SUN-131 1.5% TDS is developed for the treatment of chalazion. SUN-131 1.5% TDS is designed for local delivery of a corticosteroid, to the upper or lower eyelid. The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of a chalazion.

开始日期2017-07-31

申办/合作机构

Senju-USA, Inc.

NCT02338648 / Completed临床2期

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN 131 Transdermal System (TDS) as Compared to Placebo TDS in Adult Patients With a Chalazion

The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of chalazion based on the proportion of subjects that have complete response. Complete response is defined as the absence of any significant clinical signs of a chalazion with possible scaring or skin defects resulting from healing of the chalazion allowed.

开始日期2014-10-01

申办/合作机构

Senju-USA, Inc.

100 项与 SUN-131(Senju Pharmaceutical Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 SUN-131(Senju Pharmaceutical Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 SUN-131(Senju Pharmaceutical Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

100 项与 SUN-131(Senju Pharmaceutical Co., Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
霰粒肿	临床3期	美国	Senju-USA, Inc.	2017-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03248440 (SUN-131-03, CTgov)	临床3期	霰粒肿	263	Placebo TDS (Placebo TDS)	繭製膚糧範築觸願網廠(鬱衊獵觸範鬱蓋製憲夢) = 夢壓鬱艱艱繭衊壓願積蓋鬱壓顧鹹製糧醖顧構 (餘壓範選夢齋繭願艱願, 鏇積繭衊齋築積膚獵襯 ~ 醖齋壓製憲簾夢範獵遞) 更多	-	2021-08-05
				SUN-131 1.5% TDS (SUN-131 1.5% TDS)	繭製膚糧範築觸願網廠(鬱衊獵觸範鬱蓋製憲夢) = 網鏇網廠築窪製廠醖糧蓋鬱壓顧鹹製糧醖顧構 (餘壓範選夢齋繭願艱願, 窪窪鑰餘夢選淵繭構窪 ~ 顧鏇觸窪襯蓋構積齋遞) 更多